FilingReader Intelligence
Shanghai RAAS controlling shareholder reaches halfway point in share purchase
August 21, 2025 at 05:35 PM UTC•By FilingReader AI
Haoyingkang Medical Technology has purchased 26.4 million Shanghai RAAS Blood Products shares worth RMB 180m through centralized bidding, representing 0.40% of total share capital.
The controlling shareholder's purchase plan targets RMB 250-500m over six months, with the program now at its halfway point. Haoyingkang currently holds 22.61% of Shanghai RAAS.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shanghai RAAS Blood Products publishes news
Free account required • Unsubscribe anytime